Drugs / Factor IX
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05281718 | Aug 2022 → Mar 2024 | hemophilia A | Tulane University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02250560 | Apr 2000 → Nov 2003 | hemophilia B | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT00000582 | Jul 1978 → Jul 1979 | hemophilia A | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Factor IX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02250560 ↗ |
| Known as | Replenine-VF | “Replenine®-VF (High Purity Factor IX)” NCT02250560 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Replenine®-VF (High Purity Factor IX)” NCT02250560 ↗ |